First-Line Bevacizumab for Glioblastoma Not Likely To Be Cost-Effective
the Cancer Therapy Advisor take:
Bevacizumab has only limited effectiveness and is therefore not likely to be cost effective in treating adult patients with newly diagnosed glioblastoma multiforme, a new study published online in the Journal of Clinical Oncology has shown.
For the cost-effectiveness analysis, researchers from St Joseph's Healthcare Hamilton in Ontario, Canada, developed a Markov model to estimate the incremental cost-utility ratio (ICUR) of first-line bevacizumab in newly diagnosed glioblastoma multiforme from a Canadian public payer perspective.
Results of the analysis showed that over a 2-year time horizon, the addition of bevacizumab to radiotherapy and temozolomide resulted in an increase of 0.13 QALYs and $80,000 per patient, corresponding to an ICUR of $607,966/QALY (95% CI: $305,000/QALY to $2,550,000/QALY). The researchers found that at the $100,000/QALY willingness-to-pay threshold, bevacizumab had a 0% chance of being cost-effective.
The researchers note that second-line treatment with bevacizumab is more effective on progression and less expensive than first-line bevacizumab. The findings suggest that further research is unnecessary.
Bevacizumab has limited effectiveness and is therefore not likely to be cost effective in newly diagnosed glioblastoma multiforme.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- The International Association for the Study of Lung Cancer Publishes Liquid Biopsy Recommendations for Lung Cancer
- Stereotactic Body Radiation Therapy May Improve Overall Survival in Early-Stage Lung Cancer
- FDA Approves Ivosidenib for IDH1-Mutated Relapsed/Refractory Acute Myeloid Leukemia
- Clinical Stage at First Response May Predict Outcomes in Chronic Lymphocytic Leukemia
- Exercise and Cancer